RE:RE:Stockbuphoon Is it inconceivable to think that the MAD trials were a prerequisite by an interested suitor (Boehringher??) to partner with or sell the company to? And now that the trials are complete, with favorable results, they can move forward but not before they get their house in order by terminating the agreement with Innovon and clearing their debt with SALP so that they regain control of all assets / intellectual property which would allow them to cut the deal? If not, why else would they pay $400K to Innovon and repay their loan? Also, remember that PBI 4050 was stopped, not cancelled!
I may be naive, but no company pays their CEO just sit around with his thumb up his nose. And finally, the Thompson’s are the majority shareholders, which leads me to believe that if, there is such an arrangement in the works, the buy-in price was pre-negotiated at a much higher price than the current SP.
Time will tell!
IMHO
stockbuphoon wrote: Yes, that is an interesting thought that Boehringher should just pounce now but I would imagine that thomvest would not sell and they own the majority. It would drive price up a bit but they couldn't get control from thomvest. The deal on the table was real in 2018 and valuations in 2018 of $10 by a very well respected US Investment Bank are real as well.
Steve33 wrote:
The companies that know the clinical data on the 4050 pbi indications that almost made a supposed deal with Pierre could buy Liminal for next to nothing getting their cash and small molecule assets. That would be extremely cheap and probably the best steal ever. That is if the Alstom trial was legit.